Sven Schnaidt

7.9k total citations · 4 hit papers
22 papers, 1.9k citations indexed

About

Sven Schnaidt is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Oncology. According to data from OpenAlex, Sven Schnaidt has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 6 papers in Oncology. Recurrent topics in Sven Schnaidt's work include Diabetes Treatment and Management (15 papers), Pancreatic function and diabetes (11 papers) and Diabetes Management and Research (4 papers). Sven Schnaidt is often cited by papers focused on Diabetes Treatment and Management (15 papers), Pancreatic function and diabetes (11 papers) and Diabetes Management and Research (4 papers). Sven Schnaidt collaborates with scholars based in Germany, United States and Australia. Sven Schnaidt's co-authors include Julio Rosenstock, Nikolaus Marx, Odd Erik Johansen, Bernard Zinman, Jyothis T. George, Christoph Wanner, Mark E. Cooper, John H. Alexander, Vlado Perkovic and Egon Pfarr and has published in prestigious journals such as JAMA, Circulation and Diabetes Care.

In The Last Decade

Sven Schnaidt

20 papers receiving 1.9k citations

Hit Papers

Effect of Linagliptin vs ... 2018 2026 2020 2023 2018 2020 2020 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
    2018 756 citations Julio Rosenstock, Vlado Perkovic et al. JAMA profile →
  2. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
    2020 266 citations Milton Packer, Stefan D. Anker et al. Circulation profile →
  3. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
    2020 243 citations Stefan D. Anker, Javed Butler et al. Circulation profile →
  4. Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
    2021 226 citations Milton Packer, Javed Butler et al. Circulation profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sven Schnaidt 1.5k 622 540 517 223 22 1.9k
Egon Pfarr 1.5k 1.0× 421 0.7× 489 0.9× 497 1.0× 115 0.5× 20 1.8k
Frans Van de Werf 1.9k 1.3× 611 1.0× 666 1.2× 733 1.4× 91 0.4× 16 2.3k
Ira Gantz 1.8k 1.2× 506 0.8× 694 1.3× 767 1.5× 382 1.7× 24 2.3k
Cordula Zeller 2.0k 1.3× 982 1.6× 887 1.6× 837 1.6× 426 1.9× 42 2.6k
Frank Pistrosch 582 0.4× 461 0.7× 267 0.5× 639 1.2× 167 0.7× 44 1.7k
Robert Josse 1.7k 1.1× 426 0.7× 665 1.2× 730 1.4× 70 0.3× 17 2.2k
Samuel S. Engel 1.7k 1.1× 430 0.7× 549 1.0× 654 1.3× 67 0.3× 6 1.9k
Elena Henkel 1.6k 1.0× 529 0.9× 347 0.6× 673 1.3× 182 0.8× 34 2.3k
Anne Pernille Ofstad 1.4k 0.9× 951 1.5× 602 1.1× 518 1.0× 371 1.7× 59 2.0k
Rolf Steffensen 938 0.6× 1.4k 2.2× 1.1k 2.0× 340 0.7× 167 0.7× 62 2.7k

Countries citing papers authored by Sven Schnaidt

Since Specialization
Citations

This map shows the geographic impact of Sven Schnaidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Schnaidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Schnaidt more than expected).

Fields of papers citing papers by Sven Schnaidt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Schnaidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Schnaidt. The network helps show where Sven Schnaidt may publish in the future.

Co-authorship network of co-authors of Sven Schnaidt

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Schnaidt. A scholar is included among the top collaborators of Sven Schnaidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Schnaidt. Sven Schnaidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marx, Nikolaus, Ahmed A. Kolkailah, Julio Rosenstock, et al.. (2024). Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin. JAMA Cardiology. 9(2). 134–134. 7 indexed citations
2.
Carson, Peter E., John R. Teerlink, Michel Komajda, et al.. (2023). Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial. JACC Heart Failure. 11(4). 407–417. 7 indexed citations
3.
Filippatos, Gerasimos, Javed Butler, Dimitrios Farmakis, et al.. (2022). Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes. Circulation. 146(9). 676–686. 80 indexed citations
4.
Perkovic, Vlado, Robert D. Toto, Mark E. Cooper, et al.. (2020). Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care. 43(8). 1803–1812. 42 indexed citations
5.
Anker, Stefan D., Javed Butler, Gerasimos Filippatos, et al.. (2020). Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. Circulation. 143(4). 337–349. 243 indexed citations breakdown →
6.
Packer, Milton, Stefan D. Anker, Javed Butler, et al.. (2020). Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation. 143(4). 326–336. 266 indexed citations breakdown →
7.
8.
Wanner, Christoph, Mark E. Cooper, Odd Erik Johansen, et al.. (2020). Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. Clinical Kidney Journal. 14(1). 226–236. 7 indexed citations
9.
McGuire, Darren K., John H. Alexander, Odd Erik Johansen, et al.. (2019). Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 139(3). 351–361. 112 indexed citations
10.
Maros, Máté E., Sven Schnaidt, Péter Balla, et al.. (2019). In situ cell cycle analysis in giant cell tumor of bone reveals patients with elevated risk of reduced progression-free survival. Bone. 127. 188–198. 11 indexed citations
11.
Inagaki, Nobuya, Wenying Yang, Hirotaka Watada, et al.. (2019). Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial. Diabetology International. 11(2). 129–141. 18 indexed citations
12.
Biessels, Geert Jan, C. Verhagen, Esther van den Berg, et al.. (2019). Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. Diabetes Care. 42(10). 1930–1938. 62 indexed citations
13.
Groeneveld, Onno N., Esther van den Berg, Odd Erik Johansen, et al.. (2019). Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes. Diabetes and Vascular Disease Research. 16(6). 577–581. 24 indexed citations
14.
15.
Kahn, Steven E., Vlado Perkovic, Odd Erik Johansen, et al.. (2019). SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA. Journal of the Endocrine Society. 3(Supplement_1).
16.
Herfarth, Klaus, Peter Borchmann, Sven Schnaidt, et al.. (2018). Rituximab With Involved Field Irradiation for Early‐stage Nodal Follicular Lymphoma. HemaSphere. 2(6). e160–e160. 23 indexed citations
17.
Rosenstock, Julio, Vlado Perkovic, Odd Erik Johansen, et al.. (2018). Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 321(1). 69–69. 756 indexed citations breakdown →
18.
Hohmann, Nicolas, Raphael Reinhard, Sven Schnaidt, et al.. (2016). Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. Journal of Antimicrobial Chemotherapy. 71(8). 2241–2247. 6 indexed citations
19.
Trautmann, Agnes, Gian Marco Ghiggeri, Giuseppe Remuzzi, et al.. (2015). Risk Factors for Post-Transplant Recurrence of Steroid Resistant Nephrotic Syndrome (Srns): Results from the Podonet Registry. Universidad de Chile. 1 indexed citations
20.
Herfarth, Klaus, et al.. (2014). PD-0518: Early stage nodal follicular lymphoma using IF radiotherapy and Rituximab: Results of the MIR trial of the GLSG and ARO. Radiotherapy and Oncology. 111. S204–S204. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Egon Pfarr Breakdown of academic impact, for papers by Frans Van de Werf Breakdown of academic impact, for papers by Ira Gantz Breakdown of academic impact, for papers by Cordula Zeller Breakdown of academic impact, for papers by Frank Pistrosch Breakdown of academic impact, for papers by Robert Josse Breakdown of academic impact, for papers by Samuel S. Engel Breakdown of academic impact, for papers by Elena Henkel Breakdown of academic impact, for papers by Anne Pernille Ofstad Breakdown of academic impact, for papers by Rolf Steffensen
Rankless by CCL
2026